Lillys Oral GLP-1, Orforglipron, Delivered Superior Blood Sugar Control and Weight Loss Compared to Oral Semaglutide in Head-to-Head Type 2 Diabetes Trial Published in The Lancet
A KFF survey found that only 18% of companies with at least 200 employees, and 25% of those with 1,000 or more, cover GLP-1s primarily for weight loss
Antagonist protocols are preferred due to their ability to facilitate dual stimulation cycles, enable safer triggering, and reduce the risk of ovarian hyperstimulation syndrome, thereby optimizing oocyte yield
A common starting strategy for patients with sensitive systems is to begin with 250 mg to 500 mg in the morning, gradually increasing the dose and adding a second midday administration as tolerated
[DOI] [PMC free article] [PubMed] [Google Scholar] 170.Schroeder B.O